Skip to main content
SpringerLink
Log in

Umstellungsregime von Kurzzeit- auf Depotneuroleptika

  • Chapter
Thioxanthene

Zusammenfassung

Neuroleptika besitzen ihre Domäne in der Behandlung produktiver Psychosen. Sie sind speziell in der Therapie der schizophrenen Erkrankungen unverzichtbar. Zahlreiche Langzeituntersuchungen zum Verlauf der schizophrenen Psychosen dokumentieren einerseits eine bunte Vielfalt der Verlaufsgestalten, sprechen also klar gegen einen monolithischen und progredienten Krankheitsprozeß (Bleuler 1972; Ciompi u. Müller 1976; Huber et al. 1979). Sie zeigen aber andererseits auch, daß ca. 2/3 der einmal an einer schizophrenen Psychose erkrankten Patienten wiederholt längerfristig oder auch dauernd Neuroleptika einnehmen müssen, um, wenn überhaupt, ein prekäres psychobiologisches und psychosoziales Gleichgewicht aufrechterhalten zu können. Dem nicht zu bezweifelnden Nutzen einer neuroleptischen Medikation steht eine Reihe bedeutsamer Nebenwirkungen gegenüber, die prinzipiell das subjektive Erleben und soziale Handeln des betroffenen Patienten empfindlich beeinträchtigen können. Eine neuroleptische Therapie, besonders als Langzeitmedikation, setzt also immer eine differenzierte Nutzen-Risiko-Rechnung für den individuellen Patienten voraus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aaes-Jorgensen T, Kirk L, Petersen E, Danneskiold-Samsoe P, Jörgensen A (1983) Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)- clopenthixol decanoate in viscoleo. Psychopharmacology 81: 68–72

    Article  PubMed  CAS  Google Scholar 

  • Agrup-Andersson L, Bengtsson A, Erlandsson K, Gottfries DG, Witzel-Östlund TG (1974) Flupenthixol decanoate - controlled investigation concerning dosage. Acta Psychiatr Scand [Suppl] 255: 7–14

    Article  CAS  Google Scholar 

  • Altamura AC, Whelpton R, Curry SH (1979) Animal model for investigation for fluphenazine kinetics after administration of long-acting esters. Biopharm Drug Dispos 1: 65–72

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91

    PubMed  CAS  Google Scholar 

  • Beresford R, Ward A (1987) Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33: 31–49

    Google Scholar 

  • Bleuler M (1972) Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Thieme, Stuttgart

    Google Scholar 

  • Ciompi L, Müller C (1976) Lebensweg und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Curry SH (1977) Fluphenazin- und Fluphenazindecanoat-Plasmaspiegel beim Menschen. In: Kryspin-Exner K, Hinterhuber H, Haase H-J (Hrsg) Klinik und Pharmakologie der Lang- zeitneuroleptika. Schattauer, Stuttgart

    Google Scholar 

  • Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7: 325–331

    CAS  Google Scholar 

  • Dahl S (1988) Pharmakokinetik der Neuroleptika. Internationales Thioxanthen-Kolloquium, Hamburg, Nov 24–27

    Google Scholar 

  • Deberdt R, Elens P, Berghmans W, Heykants J, Woestenborghs R, Dreisens F, Reyntijens A, Wijingaarden I (1980) Intramuscular haloperidol decanoate for neuroleptic maintenance therapy, efficacy, dosage schedule and plasma levels. Acta Psychiatr Scand 62: 356–363

    Article  PubMed  CAS  Google Scholar 

  • DeCuyper H, Bollen J, van Praag HM, Verstraeten D (1986) Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry 148: 560–566

    Article  CAS  Google Scholar 

  • Dencker SJ, Lepp M, Malm U (1980) Clopenthixol and flupenthixol depot preparations in out-patient schizophrenics I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatr Scand 61 [Suppl 279]: 10–28

    Article  Google Scholar 

  • Dudley J, Rauw G, Hawes EM, Keegan DL, Midha KK (1983) Correlation of fluphenazine plasma levels versus clinical response in patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 7: 791–795

    Article  PubMed  CAS  Google Scholar 

  • Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and clinical response. Psychopharmacology 73: 205–210

    Article  PubMed  CAS  Google Scholar 

  • Eben E, Rüther E, Konstanzer A (1984) Psychopathological and neuroendocrinological parameters during long-term treatment with bromperidol decanoate. 14th CINP Congress, Florence

    Google Scholar 

  • El-Assra A, El-Sobky A, Kaye N, Blain PG, Wiles DH, Hajioff J, Gould SE (1983) The change from oral to depot neuroleptics in chronic schizophrenia. Clinical response and plasma levels after treatment with bromperidol or fluphenazine decanoate. Janssen Res Rep

    Google Scholar 

  • Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (1984) Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry [Sec 2] 45 (2): 50–59

    CAS  Google Scholar 

  • Escobar JI, Barron A, Kiriakos R (1983) Serum levels of fluphenazine: Effect of dosage and route of administration and relations to side effects and clinical response. Psychopharmacol Bull 19: 131–133

    Google Scholar 

  • Forsman A, Öhman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21: 396–411

    CAS  Google Scholar 

  • Gelders YG, Reyntijens AJM, Ash CW, Aerts TJL (1982) 12-months study of haloperidol decanoate in chronic schizophrenic patients. Int Pharmacopsychiatry 17: 247–254

    Google Scholar 

  • Girard M, Granter F, Schmitt L, Cotonat J, Escande M, Blanc M (1984) Premiers résultats d’une étude pharmacoeinétique de la pipothiazine et de son ester palmitique (Piportil L4) dans une population de schizphrènes. Encephale 10: 171–176

    PubMed  CAS  Google Scholar 

  • Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR (1978) Drug and family therapy in the after care treatment of acute schizophrenics. Arch Gen Psychiatry 35: 1169–1177

    PubMed  CAS  Google Scholar 

  • Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 49: 534–538

    PubMed  CAS  Google Scholar 

  • Heykants J (1978) On the pharmacokinetics of haloperidol, pimozide and penfluridol. Symposium on Modern trends in psychopharmacology and psychiatry, Kollekolle, Denmark, Sept 22–23

    Google Scholar 

  • Hogarty GE (1984) Depot neuroleptics: The relevance of psychosocial factors. J Clin Psychiatry [Sec 2] 45 (5): 34–42

    Google Scholar 

  • Hollister LE (1983) Clinical pharmacology of psychotherapeutic drugs, 2nd edn. Churchill- Livingstone, New York

    Google Scholar 

  • Hollister LE, Kim DY (1982) Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry 139: 1466–1468

    PubMed  CAS  Google Scholar 

  • Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine Verlaufs- und sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Hyttel J (1982) Preferential labelling of adenylate cyclase coupled dopamin receptors with thioxanthene neuroleptics. In: Konsaka M et al. (eds) Advances in the bioscience. Pergamon, Oxford New York

    Google Scholar 

  • Jain AK, Kelwala S, Gershon S (1988) Antipsychotic drugs in schizophrenia: current issues. Int Clin Psychopharmacol 3: 1–30

    Article  PubMed  CAS  Google Scholar 

  • Jann MW, Ereshefsky L, Sakland SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10: 315–333

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW (1975) Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. Br J Psychiatry 126: 457–461

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67: 339–352

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Prog Drug Metab 9: 111–174

    Google Scholar 

  • Jorgensen A, Overo KF (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatr Scand 61 [Suppl 279]: 41–54

    Article  Google Scholar 

  • Jorgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin L, Malm U (1982) Serum concentrations of eis (Z)-flupenthixol and prolactin in chronic schizophrenic patients, treated with flupenthixol and eis ( Z)-flupenthixol decanoate. Psychopharmacology 77: 58–65

    Google Scholar 

  • Kane JM (1987) Neuroleptic treatment of schizophrenia. In: Henn FA, DeLisi (eds) Handbook of schizophrenia, vol 2: Neurochemistry and neuropharmacology of schizophrenia. Elsevier, Amsterdam

    Google Scholar 

  • Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi JR (1983) Low dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results of relapse rates. Arch Gen Psychiatry 40: 893–896

    Google Scholar 

  • Kapfhammer HP, Rüther E (1987) Depotneuroleptika. Springer, Berlin Heidelberg New York London Paris Tokyo

    Google Scholar 

  • Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate: effectiveness, side-effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmaco-psychiatry 18: 240–245

    CAS  Google Scholar 

  • Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 72 [Suppl 322]: 51–75

    Article  Google Scholar 

  • Knudsen P, Hansen LB, Larsen AE (1985) Depot neuroleptic treatment: clinical and pharmacokinetic studies of perphenazine decanoate. Acta Psychiatr Scand 72 [Suppl 322): 5–50

    Article  Google Scholar 

  • Kuß HJ (1986) Pharmakokinetik der Depotneuroleptika. In: Das ärztliche Gespräch, Bd40. Tropon, Köln

    Google Scholar 

  • Levine J, Schooler NR, Severe J et al. (1980) Discontinuation of oral and depot neuroleptic fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. In: Cattabeni F, Raccagni G, Spano PF et al. (eds) Long-term effects of neuroleptics. Raven, New York

    Google Scholar 

  • Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry, vol 9. Plenum, New York, pp 331–361

    Google Scholar 

  • Linde OK (1983) Neuroleptika auf Esterbasis. Krankenhauspharmazie 1: 36–40.

    Google Scholar 

  • Lingjoerde O (1973) Some pharmacological aspects of depot neuroleptics. Acta Psychiatr Scand [Suppl] 246: 9–14

    Article  Google Scholar 

  • Magliozzi JR, Hollister LE, Arnold KV et al. (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138: 365–367

    PubMed  CAS  Google Scholar 

  • Marder SR, Putten T van, Mintz J, Lebell M, McKenzie J, Galtico G (1984) Maintenance therapy. New findings. In: Kane JM (ed) Drug maintenance strategies in schizophrenia. APA, Washington

    Google Scholar 

  • Marder SR, Hawes EM, Putten T van, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88: 480–483

    Article  PubMed  CAS  Google Scholar 

  • Mason AS, Granacher RP (1980) Clinical handbook of antipsychotic drug therapy. Brunner/Mazel, New York

    Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmaeology 81: 354–356

    Article  CAS  Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 a) Therapeutic blood levels of fluphenazine or RBC determinations. Psychopharmacol Bull 20: 168–170

    Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J et al. (1984 b) Clinical relevance of thioxanthene plasma levels. J Clin Psychopharmacol 4: 155–157

    Google Scholar 

  • McCreadie RG, Makie M, Wiles DH, Jorgensen A, Hansen V, Menzies C (1984) Within- individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 144: 625–629

    Article  PubMed  CAS  Google Scholar 

  • Meco G, Casacchia M, Attenni M, Iafrate A, Castellana F, Ecarill (1983) Haloperidol decanoate in schizophreniform disorders. Acta Psychiatr Belg 83: 57–68

    CAS  Google Scholar 

  • Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meitzer H (ed) Psychopharmacology. The third generation of progress. Raven, New York

    Google Scholar 

  • Miller DD, Hershey LA, Duffy JP et al. (1984) Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 4: 305–310

    Article  PubMed  CAS  Google Scholar 

  • Perris C (1976) Indications for long-term pharmacological treatment of schizophrenic syndromes. Pharmacopsychiatry 9: 146–159

    Article  Google Scholar 

  • Putten T van, May PRA, Marder SR, Wittmann LA (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187–190

    PubMed  Google Scholar 

  • Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336

    PubMed  CAS  Google Scholar 

  • Saikia JK, Jorgensen A (1983) Steady–state serum concentrations after eis ( Z)-flupenthixol decanoate in viscoleo. Psychopharmacology 8: 371–373

    Google Scholar 

  • Schindler R (1986) Früheinstellung auf Depotneuroleptika. In: Das ärztliche Gespräch, Bd 40. Tropon, Köln

    Google Scholar 

  • Sieberns S (1986) Darstellung der Depotneuroleptika. In: Das ärztliche Gespräch, Bd 40. Tropon, Köln

    Google Scholar 

  • Steiner S (1984) Modell V III. Konzept und Verwirklichung einer neuroleptischen Intensivbehandlung bei schizophrenen Patienten. Facultas, Wien

    Google Scholar 

  • Szukalski B, Lipska B, Welbel L, Nurowska K (1986) Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology 89: 428–431

    Article  PubMed  CAS  Google Scholar 

  • Tune LE, Creese I, De Paulo JR, Slavney PR, Snyder SH (1981) Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. H Nerv MentDis 169: 60–63

    Article  CAS  Google Scholar 

  • Viala A, Hou N, Ba B, Durand A, Dufour H, Agostino ND, Berda C, Jorgensen A (1984) Blood plasma kinetics of eis ( Z)-clopenthixol and fluphenazine in psychiatric patients after in-tramuscular injection of their decanoic esters. Psychopharmacology 83: 147-150

    Google Scholar 

  • Wielink PS van (1987) The clinical pharmacology of depot neuroleptics. Janssen Res Rep

    Google Scholar 

  • Wistedt B, Jorgensen A, Wiles DH (1982) A depot neuroleptic withdrawal study. Plasma concentrations of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78: 301–304

    Google Scholar 

  • Yadalam KG, Simpson GM (1988) Changing from oral to depot fluphenazine. J Clin Psychiatry 49: 346–348

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H.-P. Kapfhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Eschenallee 3, D-1000, Berlin 19, Germany

    B. Müller-Oerlinghausen

  2. Abteilung Psychiatrie, Universitäts-Nervenklinik und Poliklinik Bonn, Sigmund-Freud-Straße 25, D-5300, Bonn-Venusberg 1, Germany

    H.-J. Möller

  3. Psychiatrische Universitätsklinik, Robert-Koch-Straße 40, D-3400, Göttingen, Germany

    E. Rüther

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kapfhammer, HP. (1990). Umstellungsregime von Kurzzeit- auf Depotneuroleptika. In: Müller-Oerlinghausen, B., Möller, HJ., Rüther, E. (eds) Thioxanthene. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75194-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75194-3_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-51847-1

  • Online ISBN: 978-3-642-75194-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation